TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Visual Outcomes After Bilateral Surgical Cataract Phacoemulsification: AcrySof Toric IOL Implantation Compared to Monofocal IOL Implantation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* are willing and able to understand and sign an informed consent;~* are willing and able to attend postoperative examinations per protocol schedule;~* are ≥ 21 years of age, of either gender and any race;~* have bilateral, age related, cataracts;~* have planned cataract removal via phacoemulsification with implantation of an intraocular lens (IOL);~* are available to undergo second eye surgery within 6 weeks of the first eye surgery;~* are in good ocular health, with the exception of cataracts;~* are free of disease(s)/condition(s) listed in the Precautions section of the AcrySof Toric and monofocal package inserts: choroidal hemorrhage, chronic severe uveitis, concomitant severe eye disease, extremely shallow anterior chamber, medically uncontrolled glaucoma, microphthalmos, non-age-related cataract, proliferative diabetic retinopathy (severe), severe corneal dystrophy, severe optic nerve atrophy, irregular corneal astigmatism and color vision deficiencies.~* have regular corneal astigmatism;~* qualify for bilateral AcrySof Toric IOLs on the AcrySof Toric Calculator (www.acrysoftoriccalculator.com)~* are able to obtain pupil dilation ≥ 5.0 mm~* are able to read and understand one of the following languages: Dutch, French, German~Exclusion Criteria:~* previous corneal surgery and/or reshaping~* abnormality, disease and/or conditions of the cornea (i.e. keratoconus, corneal dystrophy, keratitis, corneal scar, etc.), which would clinically contra-indicate the implantation of a toric intraocular lens~* planned multiple procedures during cataract/IOL implantation surgery~* planned limbal relaxing incision (LRI), Excimer laser treatment or similar procedure prior to or during the course of the study~* an ocular disease and/or condition that may compromise visual acuity levels (i.e. glaucoma, diabetic retinopathy, amblyopia, etc.)~* pregnant, lactating or planning pregnancy during course of study. Subjects who become pregnant during the study will not be discontinued; however, data may be excluded from the effectiveness analyses because pregnancy can alter refraction and visual acuity results. Data will be collected on the CRF as observations.

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Toric T3 - T9 (Type: EXPERIMENTAL): Bilateral implantation of a Toric intraocular lens (IOL) models T3, T4, T5, T6, T7, T8 or T9
- Monofocal (Type: ACTIVE_COMPARATOR): Bilateral implantation of a monofocal intraocular lens (IOL) model with no toric component.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The Safety and Effectiveness of PROCRIT (Epoetin Alfa) in Patients Undergoing Elective Major Abdominal and/or Pelvic Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria: - Scheduled to undergo elective major abdominal and/or pelvic surgery with anticipated significant perioperative ((the time period describing the duration of a participants surgical procedure) blood loss (eg, greater than 500 cc and at increased risk for blood transfusion) - Hemoglobin greater than 10 g/dL and less than or equal to 13 g/dL at screening (Day -13 \[13 days prior to surgery\] to Day -11) and baseline (Day -10) - Patients with reproductive potential and their partners must practice an effective method of birth control (eg, prescription oral contraceptives, contraceptive injections, intrauterine device, double-barrier method, contraceptive patch, partner sterilization) before entry and throughout the study - Female patients with reproductive potential must have a negative urine pregnancy test within 7 days of the first dose of PROCRIT - Adequate renal (kidney) and adequate hepatic (liver) function assessed within the 21-day screening period Exclusion Criteria: - No severe Congestive Heart Failure (New York Heart Association Class IV) - No known severe stable or unstable coronary artery disease, or unstable angina - No history of deep venous thrombosis (DVT) or pulmonary embolus (PE) within 12 months before study entry (prior superficial thrombophlebitis is not an exclusion criterion) - No history of cerebrovascular accident (CVA), transient ischemic attack (TIA), Acute coronary syndrome (unstable Angina, myocardial Infarction), or other arterial thrombosis within 6 months before study entry - Not anticipated to donate perioperative autologous blood or receive transfusions within 21 days prior to baseline or to have greater than 6 transfusions perioperatively - No prior treatment with PROCRIT or any erythropoiesis-stimulating agents (ESAs) within the previous month

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PROCRIT (epoetin alfa) (Type: EXPERIMENTAL): Participants will receive PROCRIT (epoetin alfa).
- STANDARD THERAPY (Type: EXPERIMENTAL): Participants will receive standard of care.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: MRI of the Liver With Eovist

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* known hepatocellular carcinoma~* undergoing MRI of the liver~Exclusion Criteria:~* Contraindication to MRI with IV contrast

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Fecal ESBL Resurgence During Antibiotic Treatment

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~Patients with previous infection or colonization with ESBL-E admitted to one of the participating wards. -~Exclusion Criteria:~* Not able to give informed consent.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Energy Costs of Spasticity in Spinal Cord Injury: A Pilot Investigation

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* C1-T10 SCI at least 1 year post injury~* Spasticity in the legs~* Veteran~Exclusion Criteria:~* Recent increase in spasticity~* Botox within 6 months~* Phenol within 2 years~* Prior surgery for spasticity

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- 1 (Type: EXPERIMENTAL): Weaning of Spasticity Medication over a three day period while measuring Modified Ashworth Scale and Penn Spasm Frequency Score. Then titration of medication back to previous dose over a three day period.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Losartan in Bicuspid Aortic Valve Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Adults \>age 18 years and \< 65 years old~* Able to give informed consent~* Presence of a bicuspid aortic valve (functional or true bicommisural)and ascending aorta or sinus of Valsalva \>4.0cm~* No contraindications to treatment with Losartan, an Angiotensin II receptor blocker~* Able to safely participate in a 4 week drug washout period if currently taking an angiotensin II receptor blocker or ACE inhibitor.~Exclusion Criteria:~* Unable to safely take losartan due to one or more of the following:~  * Hypersensitivity to losartan or other angiotensin receptor blockers~ * Pregnancy~ * Nursing mothers~ * History of angioedema~ * Hypotension - chronically volume depleted patients~ * Hepatic or renal impairment (Cr\>1.5mg/dL)~ * Hyperkalemia (K+\>4.8)~ * Renal artery stenosis~ * Severe congestive heart failure (class III-IV)~ * Currently taking potassium supplements or salt substitutes containing potassium~ * Currently taking lithium~* Prior surgical intervention to aorta or aortic valve~* Unable or unwilling to give informed consent and follow up with study activities~* Currently taking an angiotensin receptor blocker or ACE inhibitor specifically for hypertension and are therefore unable to or are unwilling to participate in a 4 week drug washout period.~* Females of child bearing who are unwilling to practice adequate birth control throughout the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Losartan (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: HF10 Treatment of Chronic Knee Pain

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Key Inclusion Criteria:~1. Have been diagnosed with chronic, focal, neuropathic pain following orthopedic surgery(ies) of the knee(s).~2. Average pain intensity (over a period of 7 days) of ≥5 out 10 cm on the Visual Analog Scale (VAS) in the primary area of pain at enrollment.~3. Have a score of at least 4 out of 10 in Douleur Neuropathique 4 (DN4) questionnaire at the time of enrollment or eligibility verification.~4. Deemed not to have surgical loosening or other complications from the surgery that affect the stability of the knee.~5. Have stable neurological status measured by motor, sensory and reflex function as determined by the investigator.~6. Be on stable pain medications, as determined by the Investigator, for at least 28 days prior to assessing pain intensity as described in inclusion criterion #2, and be willing to stay on those medications with no dose adjustments until activation of the permanently implanted SCS device.~Key Exclusion Criteria:~1. Have radiculopathy or radicular leg pain resulting from failed back surgery.~2. Have a medical condition or pain in other area(s), not intended to be treated with SCS, that could interfere with study procedures, accurate pain reporting, and/or confound evaluation of study endpoints, as determined by the Investigator (such as primary headache diagnosis or fibromyalgia).~3. Have a current diagnosis of a progressive neurological disease such as multiple sclerosis (MS), chronic inflammatory demyelinating polyneuropathy, rapidly progressive arachnoiditis, brain or spinal cord tumor, central deafferentation syndrome, acute herniating disc, severe spinal stenosis and brachial plexus avulsion as determined by the Investigator.~4. Have a current diagnosis or condition such as a coagulation disorder, bleeding diathesis, platelet dysfunction, progressive peripheral vascular disease or uncontrolled diabetes mellitus that presents excess risk for performing the procedure as determined clinically by the Investigator.~5. Have any prior experience with SCS.~6. Have objective evidence of epidural scarring and/or any signs or symptoms of myelopathy as determined by the investigator.~7. Be benefitting from an interventional procedure to treat their trunk or limb pain (Subjects should be enrolled at least 30 days from last benefit).~8. Have an existing drug pump and/or another active implantable device such as a pacemaker.~9. Be involved in an injury claim under current litigation.~10. Have an active or unsettled worker's compensation claim.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- HF10 (Type: None): SCS stimulation with HF10 therapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Epidural Analgesia on the Parameter ANI During Childbirth

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Over 18 years,~* ASA I or II,~* No history of cardiovascular or respiratory disease~* No cardiovascular medication~* No treatment with a tocolytic agent(salbutamol, nicardipine)~* Desiring epidural analgesia at the early phase of labor pain~Exclusion Criteria:~* Too fast labour~* A pain score at or above 70 on the pain scale~* A disturbed EKG signal or extrasystoles~* Pace-Maker~* Diabetes mellitus

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- Group Saline (Type: PLACEBO_COMPARATOR): Epidural administration of saline
- Group Sufentanil (Type: EXPERIMENTAL): Epidural administration of sufentanil
- Group Lidocaine (Type: EXPERIMENTAL): Epidural administration of lidocaine

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Target-Controlled Infusion of Propofol for Flexible Bronchoscopy Sedation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients (18 years old or more) required elective flexible bronchoscopy and sedation.~Exclusion Criteria:~* American Society of Anesthesiologists classification of physical status 4 and 5, including hepatic or renal failure, severe obstructive sleep apnea and severe chronic obstructive pulmonary disease.~* Mallampati score 4 or 5.~* Significant Central nervous system disorders or other factors contributing to access consciousness difficultly.~* Men with body mass index(BMI) large than 42，Females with BMI large than 35.~* Allergic history to study drugs.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 95 Years
- Healthy Volunteers: f

Study Arms:
- Titration by target effect site concentration (Cet) 0.5μg/ml (Type: ACTIVE_COMPARATOR): The investigator will titrate the Cet to keep stable vital signs and sedative level during the flexible bronchoscopy. The criteria for titration is descried in the intervention.
- Titration by Cet 0.2μg/ml (Type: ACTIVE_COMPARATOR): The investigator will titrate the Cet to keep stable vital signs and sedative level during the flexible bronchoscopy. The criteria for titration is descried in the intervention.
- Titration by Cet 0.1μg/ml (Type: ACTIVE_COMPARATOR): The investigator will titrate the Cet to keep stable vital signs and sedative level during the flexible bronchoscopy. The criteria for titration is descried in the intervention.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Grazoprevir (MK-5172) With Peg-Interferon and Ribavirin in Participants With Chronic Genotype 2 or 3 Hepatitis C (MK-5172-012)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Body weight ≥ 88 lbs and ≤ 275 lbs~* Documented chronic Hepatitis C (CHC) GT2 or GT3 infection~* No known cirrhosis~* Agrees to use two acceptable methods of birth control during study and through 6 months after last dose of study drug~* Chest X-ray within the last 6 months~* Eye exam within the last 6 months~Exclusion Criteria:~* Known to be human immunodeficiency virus (HIV) positive or co-infected with active hepatitis B virus (positive for Hepatitis B surface antigen)~* Prior approved or investigational treatment for hepatitis C~* Evidence of hepatocellular carcinoma~* Diabetic and/or high blood pressure with clinically significant eye exam findings~* Pre-existing psychiatric condition~* Clinical diagnosis of abuse of certain substances within specified timeframes~* Known medical condition that could interfere with participation~* Active or suspected cancer within the last 5 years~* Female who is pregnant, breastfeeding, or expecting to conceive or donate eggs~* Male who is planning to impregnate partner or donate sperm~* Male with a pregnant female partner~* Chronic hepatitis not caused by HCV

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Grazoprevir 200 mg + Peg-IFN + RBV (Type: EXPERIMENTAL): Grazoprevir 200 mg in combination with Peg-IFN and RBV for 12 weeks.
- Grazoprevir 400 mg + Peg-IFN + RBV (Type: EXPERIMENTAL): Grazoprevir 400 mg in combination with Peg-IFN and RBV for 12 weeks.
- Placebo + Peg-IFN + RBV (Type: PLACEBO_COMPARATOR): Placebo to grazoprevir in combination with Peg-IFN and RBV for 12 weeks, followed by open-label Peg-IFN and RBV for an additional 12 weeks.
- Grazoprevir 800 mg + Peg-IFN + RBV (Type: EXPERIMENTAL): Grazoprevir 800 mg in combination with Peg-IFN and RBV for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: A Study of AK0529 in Infants Hospitalized With RSV

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female subjects of any race or ethnicity with an age adjusted for any prematurity of ≥1 month and ≤24 months.~* Diagnosis of RSV infection by virological.~* Subject must weigh \>3 kg at screening.~* Must have provided written informed consent for the subject to participate.~* For patients aged \<12 months, and occipitofrontal head circumference (OFHC) within the normal range for age and gender.~Exclusion Criteria:~* The subject has taken, is currently taking or requires any restricted medications.~* Subject is known to be HIV-positive (or the mother, if the potential subject is a child aged \<6 months).~* Participation in an investigational drug or device study within 30 days prior to the date of screening.~* Requires vasopressors or inotropic support at the time of enrollment.~* Concurrent gastrointestinal conditions that could, in the opinion of the investigator, prejudice absorption of the Investigational Medicinal Product (e.g. protracted vomiting, malabsorption syndrome, a history of necrotising enterocolitis with consequent short gut syndrome).~* Bronchopulmonary dysplasia or chronic lung disease requiring assisted ventilation at the time of enrollment.~* Diminished ventilatory reserve at risk for hypercapnia (e.g. pulmonary hypoplasia, sequestration syndromes, cystadenomatoid malformation, a history of surgery for diaphragmatic hernia).~* Left to right shunt meriting corrective therapy.

- Gender: ALL
- Minimum Age: 1 Month
- Maximum Age: 24 Months
- Healthy Volunteers: f

Study Arms:
- AK0529 (Type: EXPERIMENTAL): AK0529 pellets

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Volatiles in Exhaled Breath and Blood in Crohn's Disease: Validation Cohort

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: CROSS_SECTIONAL
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Age: 18-65~* BMI: 19-30~* scheduled colonoscopy~Exclusion Criteria:~* disease compromising immune system (such as HIV positive status or patients after organ transplantation~* liver disease~* active and untreated tuberculosis~* chemotherapy agents

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Entire Cohort (Type: None): This is an observational/validation study and there is no intervention involved. Exhaled air samples, blood samples, and fecal samples will be obtained.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Phase 2b Study to Evaluate RIST4721 in Palmoplantar Pustulosis (PPP)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* At least 6 months history of moderate or severe PPP, as defined by PPPASI ≥12 and PPPGA ≥3 at screening~* Males and females must be willing to use birth control as indicated~Exclusion Criteria:~* Moderate to severe psoriasis covering ≥10% of total body surface area (BSA) at screening~* Breastfeeding or pregnant~* Known immunodeficiency or subject is immunocompromised~* Active/latent infection with HBV, HCV, HIV, SARS-CoV-2 or TB~* Any topical medications for PPP excluding emollients within two weeks of randomization and systemic therapies (including phototherapy) within 4 weeks of randomization

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 74 Years
- Healthy Volunteers: f

Study Arms:
- RIST4721 400 mg (Type: EXPERIMENTAL): RIST4721 400 mg: 4 active (100 mg) tablets once daily for 12 weeks
- RIST4721 200 mg (Type: EXPERIMENTAL): RIST4721 200 mg: 2 active (100 mg) tablets + 2 placebo tablets once daily for 12 weeks
- Placebo (Type: PLACEBO_COMPARATOR): Placebo: 4 placebo tablets once daily for 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues